Pharmaceutical Business review

Vical acquires rights to Wistar’s CMV vaccine technologies

The Towne strain is an attenuated, or weakened, form of human cytomegalovirus (CMV) developed for potential vaccine applications.

Vijay Samant, president and CEO of Vical, said: “CMV is an important target for Vical, and the Wistar technology adds to our already-strong intellectual property in this field.”